Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
GILD
BuyPremium GrowerAPPROVEGilead Sciences, Inc. · Healthcare · United States · $180.6B · Avg Vol: $901M/d
Gilead Sciences generates large and durable free cash flow from its HIV franchise, funds a well-covered dividend and steady buybacks, and has strong momentum on the back of its long-acting prevention launch, with a strong quality score (Q78). The trivial insider selling is routine. Nothing adverse is known on accounting, solvency or governance beyond disclosed litigation.
COMPANY DESCRIPTION
Gilead Sciences, Inc. is a biopharmaceutical company dedicated to the research, development, and commercialization of innovative medicines, predominantly in antiviral therapies for HIV and Hepatitis, as well as oncology and inflammatory diseases. The company maintains a dominant market position in its core antiviral franchises through proprietary drugs and a strong R&D pipeline, while strategically expanding into new therapeutic areas.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.3B | 27.1B | 28.8B | 29.4B | 2.6% | 30.5B | 30.7B | 32.7B | 5.4% |
| EPS | 3.66 | 4.54 | 0.38 | 6.84 | 23.2% | -2.65 | — | — | — |
| Shares | 1.2B | 1.2B | 1.2B | 1.2B | -0.5% | 1.2B | — | — | — |
| Debt | 25.2B | 25.0B | 26.7B | 24.9B | -0.4% | 26.2B | — | — | — |
| Equity | 21.2B | 22.8B | 19.3B | 22.7B | 2.2% | — | — | — | — |
| Op CF | 9.1B | 8.0B | 10.8B | 10.0B | 3.4% | 13.6B | — | — | — |
| Inv CF | -2.5B | -2.3B | -3.4B | -4.8B | — | — | — | — | — |
| Fin CF | -6.5B | -5.1B | -3.4B | -7.7B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GILD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GILD | Gilead Sciences, Inc.(you) | $180.6B | 74 | Buy |
| AZN.ST | AstraZeneca PLC | $252.0B | 71 | Buy |
| NVS | Novartis AG | $292.3B | 75 | Buy |
| PFE | Pfizer Inc. | $159.4B | 88 | Strong Buy |
| NVO | Novo Nordisk A/S | $201.6B | 89 | Strong Buy |
| AMGN | Amgen Inc. | $233.8B | 86 | Strong Buy |
| GSK | GSK plc | $101.8B | 83 | Strong Buy |
| 4519.T | Chugai Pharmaceutical Co., Ltd. | $72.3B | 69 | Buy |
| MRK | Merck & Co., Inc. | $366.0B | 65 | Hold |
| RO.SW | Roche Holding AG | $360.3B | 85 | Strong Buy |
Peer medians: ROE 2.9% · P/E 24.4x · Gross margin 52.6%